ArteraAI Secures $20 Million in Funding to Further Personalize Cancer Therapy With Multimodal AI

SAN FRANCISCO–(BUSINESS WIRE)–ArteraAI, the developer of multimodal artificial intelligence (MMAI) based predictive and prognostic cancer tests, announced today that it has secured an additional $20 million in capital fueled by several prominent large investment funds including Prosperity7 Ventures, Singapore-based global investor EDBI, Walden Catalyst Ventures, Wilson Sonsini Goodrich & Rosati,…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks